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JR Passweg1, H Baldomero1, M Bregni2, S Cesaro3, P Dreger4, RF Duarte5, JHF Falkenburg6, N Kro¨ger7, D Farge-Bancel8,
H Bobby Gaspar9, J Marsh10, M Mohty11, C Peters12, A Sureda13, A Velardi14, C Ruiz de Elvira15 and A Madrigal16 for the
European Group for Blood and Marrow Transplantation (EBMT)
In all, 651 from 680 centers in 48 countries reported 35 660 hematopoietic SCT (HSCT) in 32 075 patients (13 470 allogeneic (42%),
18 605 autologous (58%)) to the 2011 survey. Main indications were: leukemias; 10 113 (32%; 94% allogeneic); lymphoid neoplasias;
non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, plasma cell disorders; 18 433 (57%; 12% allogeneic); solid tumours; 1573 (5%; 5%
allogeneic); and non-malignant disorders; 1830 (6%; 92% allogeneic). There were more unrelated donors than HLA identical sibling
donors (54% versus 39%); proportion of peripheral blood as stem cell source was 99% for autologous and 73% for allogeneic HSCT.
Cord blood was only used in allogeneic transplants (6% of total). In the past 10 years, the overall number of transplants has
increased by 53%. Allogeneic HSCT have doubled (from 7272 to 14 549) while, autologous have increased by 32% and continue to
increase by about 1100 HSCT per year since 2001. In the past 2 years, an increase of 42000 HSCT per year was seen. Transplant
activity is shown by team size. For allogeneic HSCT, we show use of reduced-intensity conditioning versus myeloablative
conditioning across Europe and use of post-transplant donor lymphocyte infusions with considerable variation across different
countries.
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INTRODUCTION
Hematopoietic SCT (HSCT) is an established procedure for many
acquired and congenital disorders of the hematopoietic system.1–4
Forecasts predict an on-going increase in HSCT in the near future.
The annual activity survey, describing the status of HSCT in
Europe, has become an instrument used to observe trends and to
monitor changes in technology use.5–10 The survey captures the
numbers of HSCT performed in the preceding year from each
participating team, split by indication, donor type and stem cell
source. The standardized structure of the survey over many years
and the excellent commitment by the participating teams allows
us to observe changes over time and to evaluate factors
associated with such changes. More recently, the survey has
included information on cellular transplants with hematopoietic
stem cells for non-hematopoietic use, as well as on the use of non-
hematopoietic stem and progenitor cells.11 This coincides with the
recent interest of the World Health Organization (www.who.org) in
cell and tissue transplants and further stresses the need for
adequate and timely information.12
The European Group for Bone Marrow Transplantation (EBMT)
analyses in previous years have shown an increase in the annual
absolute HSCT numbers and transplant rates (number of HSCT/10
million inhabitants) of about 4–13% (median 8%) for allogeneic
and of 1.5–9.5% (median 4%) for autologous HSCT.
This report is based on the 2011 survey data. In addition to
transplant rates and indications, stem cell source and donor type
in allogeneic HSCT, we provide data on proportions of transplants
done in low, intermediate and high transplanting centers and data
on important differences among countries in the use of reduced
intensity (RIC) versus myeloablative conditioning and in the use of
DLI post transplant for recipients of allogeneic HSCT.
PATIENTS AND METHODS
Data collection and validation
Participating teams were requested to report data for 2011 by indication,
stem cell source and donor type as listed in Table 1. Quality control
measures included several independent systems: conﬁrmation of validity
of the entered data by the reporting team, selective comparison of the
survey data with MED-A data sets in the EBMT Registry database, cross-
checking with the National Registries and onsite visits of selected teams.
Teams
A total of 680 centers from 48 countries were contacted for the 2011
survey (39 European and 9 afﬁliated countries); of which 651 teams from
46 countries (37 European, 9 afﬁliated countries) reported their numbers.
This corresponds to a 96% return rate and includes 537 active EBMT
member teams. Fourteen active teams failed to report in 2011 while 15
teams reported no activity due to transplant program development or
closure.
Contacted teams are listed in the appendix in alphabetical order by
country, city, EBMT center code, with their reported numbers of ﬁrst and
total HSCT and of ﬁrst allogeneic and autologous HSCT. The WHO regional
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ofﬁce deﬁnitions (www.who.org) were used to classify countries as
European or Non-European. According to information received, there
were no blood or marrow transplants performed in Albania, Andorra,
Armenia, Georgia, Liechtenstein, Malta, Moldavia, Monaco, Montenegro
and San Marino in 2011. Nine non-European countries participated in the
2011 EBMT survey: Algeria, Iran, Israel, Jordan, Lebanon, Nigeria, Saudi
Arabia, South Africa and Tunisia. Their data, 6% of the total data set, are
included in all the analyses.
Deﬁnitions
Patient and transplant numbers. Wherever appropriate, patient numbers
corresponding to the number of patients receiving a ﬁrst transplant and
transplant numbers reﬂecting the total number of transplants performed
are listed. Multiple transplants may include multiple transplants deﬁned as
subsequent transplants within a planned double or triple autologous or
allogeneic transplant protocol, and retransplants (autologous or allo-
geneic) deﬁned as unplanned HSCT for rejection or relapse after a previous
HSCT.
Information on stem cell source includes BM, peripheral blood or cord
blood; transplants with more than one source were categorized as cord
blood HSCT if cord blood was present or peripheral blood HSCT if BM and
peripheral blood were used. Information on use of RIC transplants, as
deﬁned by EBMT, was collected.
Information on additional cellular therapies was subdivided into: HSC for
non-hematopoietic use; non-hematopoietic stem cell therapies; MSC
therapies for rejection or GvHD prevention/treatment; and donor
lymphocyte infusions. Collection of information was harmonized with
Table 1. Numbers of hematopoietic SCTs in Europe 2011 by indication, donor type and stem cell source
HLA-identical sibling Mis-matched
relative
Unrelated Autologous Total
BM PB CB BM PB CB BM PB CB BM PB Allogeneic Autologous
Leukemias 756 2880 8 151 312 4 841 4016 503 28 614 9471 642
AML 316 1417 4 76 163 302 1897 230 25 482 4405 507
Early disease 230 974 2 30 80 182 991 120 20 413 2609 433
Advanced disease 86 443 2 46 83 120 906 110 5 69 1796 74
ALL 283 585 3 44 90 3 306 619 164 1 75 2097 76
Early disease 179 403 19 38 170 382 78 1 55 1269 56
Advanced disease 104 182 3 25 52 3 136 237 86 20 828 20
CML 38 118 3 13 1 29 173 16 1 391 1
Early disease 23 42 1 7 15 69 6 163
Advanced disease 15 76 2 6 1 14 104 10 1 228 1
Myelodysplastic disorders 98 464 20 37 160 866 75 1 13 1720 14
Myeloproliferative disorders 11 114 1 5 2 18 193 10 354
CLL 10 182 3 7 26 268 8 1 43 504 44
Lymphoproliferative disorders 80 783 54 50 101 1001 66 75 16 223 2135 16 298
Plasma cell—myeloma 25 219 2 10 29 280 13 15 8326 578 8341
Plasma cell—other 2 10 1 17 3 245 33 245
Hodgkin’s lymphoma 11 140 31 14 15 134 13 21 2045 358 2066
Non-Hodgkin’s lymphoma 42 414 21 26 56 570 37 39 5607 1166 5646
Solid tumors 9 8 1 40 8 5 3 66 1433 74 1499
Neuroblastoma 6 1 23 4 2 3 31 402 39 433
Soft tissue sarcoma 1 7 1 1 4 37 10 41
Germinal tumors 1 4 351 1 355
Breast cancer 1 54 1 54
Ewing 1 2 1 4 1 2 9 211 11 220
Other solid tumors 2 2 6 2 18 378 12 396
Non-malignant disorders 577 260 37 75 107 1 311 187 137 11 127 1692 138
BM failure—SAA 200 130 3 11 19 128 82 22 595
BM failure—other 51 17 4 6 6 44 24 12 164
Hemoglobinopathies—
thalassemia
150 59 11 21 24 21 10 5 301
Hemoglobinopathies—other 51 25 10 5 4 6 3 2 106
Primary Immune deficiencies 88 20 6 26 38 1 75 53 56 6 5 363 11
Inherited disorders of
Metabolism
34 7 3 6 15 32 12 37 4 4 146 8
Auto immune disease 3 2 1 5 3 3 1 118 17 119
Others 28 10 1 2 5 14 26 12 28 98 28
Total Patients 1450 3941 46 283 514 5 1275 5235 721 180 18 425 13 470 18 605
Additional transplants 44 286 43 137 1 55 453 60 6 2500 1079 2506
Total Transplants 1494 4227 46 326 651 6 1330 5688 781 186 20 925 14 549 21 111
Abbreviations: CB¼ cord blood; PB¼peripheral blood; SAA¼ severe aplastic anemia.
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similar surveys carried out by EULAR (European League against Rheuma-
tism; www.eular.org) and TERMIS-EU (Tissue Engineering and Regenerative
Medicine International Society; www.termis.org).11
Transplant rates
Transplant rates, deﬁned as numbers of HSCT per 10 million inhabitants,
were computed for each country without adjustments for patients who
crossed borders and received their HSCT in a foreign country. Population
numbers were obtained from the US census bureau database (http://
www.census.gov/population/international/data/idb/rank.php).
Analysis
Wherever appropriate, absolute numbers of transplanted patients or
transplants or transplant rates are shown for speciﬁc countries, indications
or transplant techniques. Team size was deﬁned as low, intermediate or
high based on 1–25, 25–75 and475 patients transplanted. Team size was
deﬁned separately for autologous and allogeneic HSCT. To estimate the
percentage of allogeneic HSCT done using a RIC regimen and the
percentage of allogeneic HSCT that are followed by a DLI, the transplant
years 2008–2011 were averaged and compared across countries. For this
comparison, only countries with 4100 allogeneic HSCT annually were
included.
RESULTS
2011 Data
Participating teams in 2011. Of the 651 teams, 403 (62%) did both
allogeneic and autologous transplants; 226 (35%) restricted their
activity to autologous HSCT only and 12 teams (2%) to allogeneic
transplants only. Ten teams (1%) reported having performed no
transplants in 2011. The list of the participating teams can be
downloaded as a Supplementary informaton ﬁle online.
Numbers of patients and transplants
A total 32 075 patients were transplanted in 2011. Of these, the
ﬁrst transplant for 13 470 (42%) was allogeneic, while the ﬁrst
transplant for 18 605 (58%) was autologous.
Furthermore, there were 2073 re-transplants (1018 allogeneic/
1055 autologous) and 1512 multiple transplants (61 allogeneic/
1451 autologous), bringing the total to 35 660 HSCT procedures,
14 549 allogeneic (41%) and 21 111 autologous (59%) performed
in 2011, which is an increase of 7% compared with 2010.13
Indications for HSCT in 2011 are listed in detail in Table 1 and
their distribution is illustrated in Figures 1a and b: allogeneic HSCT
and autologous HSCT, respectively. Main indications were
lymphoid neoplasias, including non-Hodgkin’s lymphoma, Hodg-
kin’s lymphoma and plasma cell disorders, leukemias, solid
tumours and non-malignant disorders. As seen in previous years,
the majority of HSCT for lymphoid malignancies were autologous
while leukemia is treated more commonly using stem cells from
allogeneic donors. Autologous HSCT for non-malignant disorders
predominantly include patients with autoimmune disorders.
As compared with the previous year, the total number of
transplants increased by 6.9% (9% allogeneic HSCT and 5.5%
autologous HSCT). The number of unrelated donor transplants
increased by 10% from 7098 to 7799.13 Areas of important
changes in transplant activity were an increase in AML ﬁrst
remission allo HSCT by 14%, and in more advanced disease by 9%,
and an increase in myelodysplastic syndrome/secondary AML
allogeneic HSCT by 20%. Allogeneic HSCT for CLL increased by
24%, there was a decrease of myeloproliferative neoplasm
allogeneic HSCT by 26% and for CML not in chronic phase by
11%. In non-malignant diseases, there was an increase in
allogeneic HSCT for aplastic anemia by 19%, for thalassemia by
39%, primary immune deﬁciencies by 10% and in inherited
disorders of metabolism by 33%. For autologous transplants, the
main increase could be seen for plasma cell disorders (10%) and
non-Hodgkin’s disorder (3%) while the autoimmune disorders
decreased by 20%, but in general, the changes in trends for
autologous HSCT were much less dramatic.
Stem cell source and donor type
There were clear differences in the use of stem cell source
between autologous and allogeneic HSCT. Of the 21 111
autologous transplants, 186 (1%) were BM derived and 20 925
(99%) were derived from peripheral blood stem cells or from
combined peripheral blood and BM.
Of the 14549 allogeneic transplants, 3150 (22%) were BM, 10566
(72%) were peripheral blood and 833 (6%) were cord blood
transplants (Figure 2a). Cord blood was used as the stem cell source
for 46 (0.8%) of HLA-identical siblings, 6 (0.6%) from other family
members and 781 (10%) of unrelated donors. No autologous cord
blood HSCT was reported for 2011. The highest incidence of cord
blood transplants from unrelated donors was seen in France, Spain
and Italy: 424 (54% of all unrelated cord blood HSCT).
The choice of stem cell source differed by main indication for
all types of allogeneic HSCT. BM remained the preferred source
of stem cells for allogeneic transplants for non-malignant
disorders (57%).
AML, 4405, 33%
ALL, 2097, 15%
CML, 391, 3%
MDS/MPS, 2074,
15%
CLL, 504, 4%
PCD, 611, 4%
HD, 358, 3%
NHL, 1166, 9%
Solid tumors, 74,
0%
BMF, 759, 6%
Hemo/thal, 407, 3%
PID, 363, 3%
IDM, 146, 1% AID, 17, 0.1%
Others, 98, 1%
Leukemias, 642,
3.5%
PCD, 8586, 46.1%
HD, 2066, 11.1%
NHL, 5646, 30.3%
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2.3%
Soft tissue sarcoma,
41, 0.2%
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355, 1.9%
Ewing, 220, 1.2%
Other solid tumors,
396, 2.1% Non malignant, 19,
0.1%
AID, 119, 0.6%
Others , 28, 0.2%
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Figure 1. Absolute numbers and relative proportions of indications
for an HSCT in Europe in 2011. (a) Proportions of disease indications
for an allogeneic HSCT in Europe in 2011. (b) Proportions of
disease indications for an autologous HSCT in Europe in 2011.
BMF¼bone marrow failure; HD¼ Hodgkin’s disease; IDM¼ inherited
disorders of metabolism; MDS¼myelodysplastic syndrome; MPS¼
myeloproliferative syndrome; NHL¼non-Hodgkin’s lymphoma;
PCD¼plasma cell disroder; PID¼primary immunodeficiency.
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Donors for the 14 549 allogeneic HSCT were HLA-identical
siblings (5677 (39%) BM or peripheral blood donors; 46 (0.0.3%)
targeted cord blood HSCT), other family members (983; 7%),
syngeneic twin donors (44; 0.3%), unrelated BM or peripheral
blood donors (7,018; 48%) or unrelated cord blood donors
(781; 5%) Figure 2b). The percentage of unrelated donor
HSCT continues to increase and has reached 54% of all allogeneic
HSCT in 2011.14
RIC
Numbers of RIC HSCT continued to increase from 1436 in 2000 to
5567 in 2011 (Figure 3a).15 RIC conditioning was used for 38% of
all allogeneic HSCT, a proportion similar to that of last year’s
survey. In countries performing 4100 allogeneic HSCT per year,
the highest percentage of RIC HSCT was seen in the Netherlands
(60%). In the United Kingdom, Denmark and France 450% of
allogeneic HSCT were performed using RIC but the percentages
vary widely with some countries having o20% of transplants
done with RIC conditioning (Figure 3b).
Donor lymphocyte infusions
In 1997, 305 patients were reported as having received DLI
infusions after transplant; this has increased to 2279 in 2011 and
corresponds to 16% of patients with an allogeneic HSCT
(Figure 4a). In countries performing 4100 HSCT per year,
the highest percentage of allogeneic HSCT receiving DLI post
transplant can be seen in the Netherlands (32%), with a number
of countries in which o5% of transplants are followed by DLI
(Figure 4b).
Additional cellular therapies
In all, 28 teams from 13 countries reported having treated 281
patients with hematopoietic stem cells for non-hematopoietic use
HLA identical
sibling/twin
Other relative UnrelatedBM PBSC
Stem cell source in allogeneic HSCT in 2011 Donor type in allogeneic HSCT in 2011
CB
Donor type N HSCT %
HLA identical sibling/twin 5767 39.6
Other relative 983 6.8
Unrelated 7799 53.6
Stem cell source N HSCT %
BM 3150 21.7
PBSC 10566 72.6
CB 833 5.7
Figure 2. Donor type and stem cell source in allogeneic HSCT. (a) Stem cell source in allogeneic HSCT in 2011. (b) Donor type in allogeneic
HSCT in 2011. CB¼ cord blood.
% of patients receiving reduced intensity HSCT during
 the years 2007-2011 in countries performing >100 
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Figure 3. RIC in allogeneic HSCT. (a) Absolute numbers of RIC HSCT 2000–2011. (b) Percentage of patients receiving RIC HSCT during the years
2007–2011 in countries performing 4100 allogeneic HSCT per year.
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in 2011. The main indications were cardiovascular, 190 (all
autologous); neurological, 26 (4 autologous); tissue repair, 55 (50
autologous) and epithelial: 10 (9 autologous). In addition, 330
patients in 71 teams and 16 countries received MSCs for
prevention/treatment of GvHD (248), prevention/treatment of
graft failure (59) and for unspeciﬁed reasons (23).
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Figure 4. DLI in allogeneic HSCT. (a) Absolute numbers of patients receiving DLI since 1997. (b) Percentage of patients receiving DLI during
the years 2007–2011 in countries performing 4100 allogeneic HSCT per year.
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Figure 5. Transplant rates in Europe (¼ total number of HSCT per 10 million inhabitants) by participating country. (a) Allogeneic transplant
rates per10 million population in 2011. (b) Autologous transplant rates per 10 million population in 2011.
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Transplant rates and team size
Transplant rates differed substantially between participating
European countries (Figure 5a: allogeneic HSCT; Figure 5b:
autologous HSCT). These differences related to all types of HSCT.
Transplant rates per 10 million inhabitants for autologous HSCT
vary from 14.2 in Ukraine to 519 in Italy, median 151. Transplant
rates for allogeneic HSCT vary from either 0 in several countries or
1.3 in Ukraine to 547 in Israel and 380 in Germany, median 109.
To illustrate the impact of team size, transplant teams were
grouped into low (1–25 HSCT) intermediate (25–75) HSCT and
high (more than 75 HSCT) teams separately for autologous and
allogeneic procedures.
In all, 415 of the 651 teams reporting in 2011 performed an
allogeneic HSCT in 2011, 203 teams (49% and 2594 HSCT)
reportedo25 transplants, 169 teams (41% and 7219 HSCT); 25–75
HSCT and 43 teams (10% and 4736 HSCT) performed 475 HSCT
in 2011.
Also, 629 of the 651 teams reporting in 2011 performed an
autologous HSCT in 2011, 304 teams (48% and 3691 HSCT)
reportedo25 transplants, 267 teams (43% and 11 643 HSCT); 25–
75 HSCT and 58 teams (9% and 5777 HSCT) performed475 HSCT
in 2011. Data are shown in Table 2. It is evident that close to
half of the teams fall into the category of low-frequency
teams performing o20% of all transplants, be they autologous
or allogeneic HSCTs.
DISCUSSION
The EBMT activity survey has been conducted annually since 1990.
The 2010 survey had, for the ﬁrst time, reported430 000 patients
transplanted in a given year. This trend continues with an
additional increase by 7% in 2011. This 2011 report is on 35 660
transplants.
HSCT continues to increase for some indications but not for
others. Of interest is an important growth of allogeneic HSCT for
myelodysplastic syndrome, CLL and for non-malignant disorders,
in particular marrow failure and inherited disorders of metabolism.
Some indications are decreasing, such as allogeneic transplants for
myeloproliferative neoplasias. This is possibly due to the devel-
opment of new drugs such as janus kinase 2 inhibitors. A success
of these drugs may result in decreasing needs for transplant in
these diseases similar to the effect the development of tyrosine
kinase inhibitors (TKI) had on transplant rates for CML. Of interest,
CML was the main indication for allogeneic HSCT in the 1990s, and
the highest number of allogeneic HSCT for CML was 1396 in 1999,
whereas in 2011 the number of transplants had reduced to 391,
which corresponds to 1/4 of the activity before tyrosine kinase
inhibitor availability.
We show data on the use of RIC for allogeneic HSCT and in the
use of DLI after allogeneic HSCT. Of interest is the wide variation in
the use of RIC conditioning and of DLI, which varies widely across
countries. As we do not know the precise indications for the
choice of these interventions, the appropriateness cannot be
analyzed. Discrepancies have to be discussed, however, and there
appears to be a need for more standardization in the ﬁeld as
differences up to threefold in the use of a given technology must
be considered as evidence for uncertainty about appropriate use.
Finally, there is a description of 2011 transplants by team size. It
is obviously beyond the scope of this paper to discuss in detail
appropriateness of decision by health planners on how transplant
units are established, but we have to acknowledge the fact that
approximately half of the centers fall into the category of low-
frequency centers witho25 HSCTs in a given category (allogeneic
and autologous HSCTs being analyzed separately) and that these
low-frequency centers perform o20% of all HSCTs. In a previous
paper by the EBMT activity survey, the relationship between
transplant rates and team density have been discussed.5 The
principles of concentrating activity to few centers in order to
maintain the highest degrees of team experience and as a
consequence better treatment quality, which also needs to be
proven, versus the principle of easy access to care, proximity of
patients to the nearest transplant center and as a consequence
smaller team size, cannot be easily resolved.
Last, in spite of the economic crisis in Europe, there does not
appear to be a decrease in transplant activity since 2009 but rather
a continued annual increase in the use of HSCT technology.
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